Telomir Pharmaceuticals (TELO) said Friday it was able to stabilize both Silver(I) and the highly reactive Silver(II) in a biologically compatible form with its Telomir-1 compound.
The company said the Telomir-1 compound would help overcome hurdles in silver-based medical applications and open up new possibilities for advanced antimicrobial treatments, wound care, and infection-resistant medical coatings.
The silver-based medical treatments market is rapidly growing, with the silver wound dressings segment valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030, the company said.
Additionally, the company added that the antimicrobial coatings market, which includes silver-infused medical devices, hospital surfaces, and implants, is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031.
Telomir said it is advancing research and development to explore clinical applications of stabilized Silver(II) complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.
Shares of the company rose 5% in recent premarket trading.
Price: 4.40, Change: +0.22, Percent Change: +5.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。